Evidence map›Paper›PMID 40224321›Full record

ReviewFrontiers in allergy2025

Rémi Pereira De Oliveira, Clément Droillard, Gilles Devouassoux, Manuel Rosa-Calatrava

Abstract readReview
In one paragraph

Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rémi Pereira De OliveiraCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Clément DroillardCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Gilles DevouassouxCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Manuel Rosa-CalatravaCIRI, Centre International de Recherche en Infectiologie, Team VirPath, Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a heterogenous inflammatory bronchial disease involving complex mechanisms, several inflammatory pathways, and multiples cell-type networks. Bronchial inflammation associated to asthma is consecutive to multiple aggressions on epithelium, such as microbiologic, pollutant, and antigenic agents, which are responsible for both T2 and non-T2 inflammatory responses and further airway remodeling. Because asthma physiopathology involves multiple crosstalk between several cell types from different origins (epithelial, mesenchymal, and immune cells) and numerous cellular effectors, no single and/or representative

Indexed as

asthmaexacerbationin vitro modelphysiopathologyviral infection

Identifiers

PMID40224321
PMCPMC11987631

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.